Scholarlink

<p>This study utilized plasmonic photothermal therapy (PPTT) based on localized surface plasmon resonance (LSPR) to treat the MDA-MB-231 breast cancer cell line. Initially, theoretical calculations of absorption cross-sections for various sizes and quantities of gold nanoparticles were performed via COMputational SOLutions (COMSOL) software to determine the appropriate incident wavelength for hyperthermia. The breast cancer cell lines were then treated with spherical gold nanoparticles, approximately 50 nm in size, at concentrations of 10, 20, 30, 40, 50, 60, 70, 100, and 130 μg/mL. The biocompatibility of the nanoparticles and their IC50 values were assessed via the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay. Subsequently, concentrations below the IC50 were selected for in vitro photothermal therapy. The cytotoxicity of the gold nanoparticles was concentration dependent, with 70 μg/mL identified as the IC50. During in vitro photothermal treatment, significant cell death was observed in the MDA-MB-231 breast cancer cell line incubated with gold nanoparticles and exposed to a laser beam (532 nm, 90 mW, 10 min), with increasing nanoparticle concentrations increasing the effect. The findings of this study demonstrate the feasibility of treating MDA-MB-231 breast cancer cell lines in vitro with plasmonic gold nanoparticles through photothermal therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Plasmonic Photothermal Therapy (PPTT) with Plasmonic Gold Nanoparticles in the Breast Cancer Cell Line “MDA-MB-231”: A Theoretical and Experimental Study

  • 期刊论文

  • 发表日期：

    2025年8月25日

查看全文
  • Seyedeh Saba Mousavifard,
  • Somayeh Salmani,
  • Latifeh Karimzadeh Bardeei,
  • Mohammad Hossein Majles Ara

摘要

This study utilized plasmonic photothermal therapy (PPTT) based on localized surface plasmon resonance (LSPR) to treat the MDA-MB-231 breast cancer cell line. Initially, theoretical calculations of absorption cross-sections for various sizes and quantities of gold nanoparticles were performed via COMputational SOLutions (COMSOL) software to determine the appropriate incident wavelength for hyperthermia. The breast cancer cell lines were then treated with spherical gold nanoparticles, approximately 50 nm in size, at concentrations of 10, 20, 30, 40, 50, 60, 70, 100, and 130 μg/mL. The biocompatibility of the nanoparticles and their IC50 values were assessed via the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay. Subsequently, concentrations below the IC50 were selected for in vitro photothermal therapy. The cytotoxicity of the gold nanoparticles was concentration dependent, with 70 μg/mL identified as the IC50. During in vitro photothermal treatment, significant cell death was observed in the MDA-MB-231 breast cancer cell line incubated with gold nanoparticles and exposed to a laser beam (532 nm, 90 mW, 10 min), with increasing nanoparticle concentrations increasing the effect. The findings of this study demonstrate the feasibility of treating MDA-MB-231 breast cancer cell lines in vitro with plasmonic gold nanoparticles through photothermal therapy.